0001211805 false --12-31 Q3 P5Y
0001211805 2022-01-01 2022-09-30 0001211805 2022-11-08 0001211805
2022-09-30 0001211805 2021-12-31 0001211805 2021-01-01 2021-09-30
0001211805 2022-07-01 2022-09-30 0001211805 2021-07-01 2021-09-30
0001211805 us-gaap:CommonStockMember 2021-12-31 0001211805
us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31
0001211805 us-gaap:RetainedEarningsMember 2021-12-31 0001211805
us-gaap:CommonStockMember 2020-12-31 0001211805
us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31
0001211805 us-gaap:RetainedEarningsMember 2020-12-31 0001211805
2020-12-31 0001211805 us-gaap:CommonStockMember 2022-06-30
0001211805 us-gaap:AdditionalPaidInCapitalMember 2022-06-30
0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-06-30 0001211805 us-gaap:RetainedEarningsMember 2022-06-30
0001211805 2022-06-30 0001211805 us-gaap:CommonStockMember
2021-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember
2021-06-30 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30
0001211805 us-gaap:RetainedEarningsMember 2021-06-30 0001211805
2021-06-30 0001211805 us-gaap:CommonStockMember 2022-01-01
2022-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember
2022-01-01 2022-09-30 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01
2022-09-30 0001211805 us-gaap:RetainedEarningsMember 2022-01-01
2022-09-30 0001211805 us-gaap:CommonStockMember 2021-01-01
2021-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember
2021-01-01 2021-09-30 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01
2021-09-30 0001211805 us-gaap:RetainedEarningsMember 2021-01-01
2021-09-30 0001211805 us-gaap:CommonStockMember 2022-07-01
2022-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember
2022-07-01 2022-09-30 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01
2022-09-30 0001211805 us-gaap:RetainedEarningsMember 2022-07-01
2022-09-30 0001211805 us-gaap:CommonStockMember 2021-07-01
2021-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember
2021-07-01 2021-09-30 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01
2021-09-30 0001211805 us-gaap:RetainedEarningsMember 2021-07-01
2021-09-30 0001211805 us-gaap:CommonStockMember 2022-09-30
0001211805 us-gaap:AdditionalPaidInCapitalMember 2022-09-30
0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-09-30 0001211805 us-gaap:RetainedEarningsMember 2022-09-30
0001211805 us-gaap:CommonStockMember 2021-09-30 0001211805
us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001211805
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30
0001211805 us-gaap:RetainedEarningsMember 2021-09-30 0001211805
2021-09-30 0001211805 MYSZ:SellingPlatformMember 2022-01-01
2022-09-30 0001211805 us-gaap:FairValueInputsLevel1Member
2022-09-30 0001211805 us-gaap:FairValueInputsLevel2Member
2022-09-30 0001211805 us-gaap:FairValueInputsLevel3Member
2022-09-30 0001211805 us-gaap:FairValueInputsLevel1Member
2021-12-31 0001211805 us-gaap:FairValueInputsLevel2Member
2021-12-31 0001211805 us-gaap:FairValueInputsLevel3Member
2021-12-31 0001211805 MYSZ:CostOfRevenuesMember 2022-01-01
2022-09-30 0001211805 MYSZ:CostOfRevenuesMember 2021-01-01
2021-09-30 0001211805 MYSZ:CostOfRevenuesMember 2022-07-01
2022-09-30 0001211805 MYSZ:CostOfRevenuesMember 2021-07-01
2021-09-30 0001211805 us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01 2022-09-30 0001211805
us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30
0001211805 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01
2022-09-30 0001211805 us-gaap:ResearchAndDevelopmentExpenseMember
2021-07-01 2021-09-30 0001211805
us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30
0001211805 us-gaap:SellingAndMarketingExpenseMember 2021-01-01
2021-09-30 0001211805 us-gaap:SellingAndMarketingExpenseMember
2022-07-01 2022-09-30 0001211805
us-gaap:SellingAndMarketingExpenseMember 2021-07-01 2021-09-30
0001211805 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01
2022-09-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember
2021-01-01 2021-09-30 0001211805
us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30
0001211805 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01
2021-09-30 0001211805 MYSZ:ConsultantFourteenMember 2019-07-31
0001211805 MYSZ:ConsultantFourteenMember 2019-07-01 2019-07-31
0001211805 MYSZ:ConsultantFourteenMember MYSZ:AtExecutionMember
2019-07-31 0001211805 MYSZ:ConsultantFourteenMember
MYSZ:AtExecutionMember 2019-07-01 2019-07-31 0001211805
MYSZ:ConsultantFourteenMember 2022-01-01 2022-09-30 0001211805
MYSZ:ConsultantFourteenMember 2021-01-01 2021-09-30 0001211805
MYSZ:ConsultantFourteenMember 2022-07-01 2022-09-30 0001211805
MYSZ:ConsultantFourteenMember 2021-07-01 2021-09-30 0001211805
MYSZ:TwoThousandSeventeenEmployeePlanMember 2017-03-31 0001211805
MYSZ:EmployeesAndDirectorsMember 2020-05-25 0001211805
MYSZ:EmployeesAndDirectorsMember srt:MaximumMember 2020-05-25
0001211805 MYSZ:EmployeesAndDirectorsMember srt:MinimumMember
2020-05-25 0001211805 MYSZ:EmployeesAndDirectorsMember 2022-01-01
2022-09-30 0001211805 MYSZ:EmployeesAndDirectorsMember 2021-01-01
2021-09-30 0001211805 MYSZ:TwoThousandSeventeenEmployeePlanMember
2020-08-09 0001211805 MYSZ:TwoThousandSeventeenEmployeePlanMember
2020-08-10 0001211805
MYSZ:TwoThousandSeventeenConsultantIncentivePlanMember 2020-08-09
0001211805 MYSZ:TwoThousandSeventeenConsultantIncentivePlanMember
2020-08-10 0001211805
MYSZ:TwoThousandSeventeenConsultantIncentivePlanMember 2021-12-29
0001211805 MYSZ:TwoThousandSeventeenConsultantIncentivePlanMember
2021-12-30 0001211805
MYSZ:TwoThousandSeventeenEquityIncentivePlanMember
MYSZ:RonenLuzonMember 2022-09-28 2022-09-29 0001211805
MYSZ:TwoThousandSeventeenEquityIncentivePlanMember
MYSZ:OrKlesMember 2022-09-28 2022-09-29 0001211805
MYSZ:TwoThousandSeventeenEquityIncentivePlanMember
MYSZ:BillyPardoMember 2022-09-28 2022-09-29 0001211805
MYSZ:TwoThousandSeventeenEquityIncentivePlanMember
MYSZ:IliaTurchinskyMember 2022-09-28 2022-09-29 0001211805
MYSZ:TwoThousandSeventeenEquityIncentivePlanMember
MYSZ:EzequielJavierBrandwainMember 2022-09-28 2022-09-29 0001211805
MYSZ:TwoThousandSeventeenEquityIncentivePlanMember 2022-09-28
2022-09-29 0001211805 MYSZ:TwoThousandSeventeenEmployeePlanMember
2022-01-01 2022-09-30 0001211805
MYSZ:TwoThousandSeventeenEmployeePlanMember 2021-01-01 2021-09-30
0001211805 MYSZ:TwoThousandSeventeenEmployeePlanMember 2022-07-01
2022-09-30 0001211805 MYSZ:TwoThousandSeventeenEmployeePlanMember
2021-07-01 2021-09-30 0001211805 MYSZ:NorthEmpireLLCMember
MYSZ:SecuritiesPurchaseAgreementMember 2018-08-06 2018-08-07
0001211805 MYSZ:NorthEmpireLLCMember 2018-08-01 2018-08-02
0001211805 MYSZ:NorthEmpireLLCMember 2018-09-26 2018-09-27
0001211805 MYSZ:FidelityVentureCapitalLtdMember
MYSZ:MrDrorAtzmonMember 2021-07-04 2021-07-05 0001211805
MYSZ:FidelityVentureCapitalLtdMember MYSZ:MrDrorAtzmonMember
2021-07-05 0001211805 MYSZ:FidelityVentureCapitalLtdMember
MYSZ:MrDrorAtzmonMember 2022-04-10 2022-04-11 0001211805
MYSZ:OrgadMember 2022-02-07 0001211805 MYSZ:OrgadMember 2022-02-07
2022-09-30 0001211805 MYSZ:OrgadMember 2022-07-01 2022-09-30
0001211805 MYSZ:OrgadMember 2021-01-01 2021-12-31 0001211805
MYSZ:OrgadMember 2022-01-01 2022-09-30 0001211805 MYSZ:OrgadMember
MYSZ:EightEqualQuarterlyInstalmentsMember 2022-01-01 2022-09-30
0001211805 MYSZ:FashionAndEquipmentECommercePlatformMember
2022-01-01 2022-09-30 0001211805 MYSZ:SaasSolutionsMember
2022-01-01 2022-09-30 0001211805
MYSZ:FashionAndEquipmentECommercePlatformMember 2022-07-01
2022-09-30 0001211805 MYSZ:SaasSolutionsMember 2022-07-01
2022-09-30 0001211805
MYSZ:FashionAndEquipmentECommercePlatformMember 2022-09-30
0001211805 MYSZ:SaasSolutionsMember 2022-09-30 0001211805
us-gaap:SubsequentEventMember MYSZ:SharePurchaseAgreementMember
MYSZ:NaizBespokeTechnologiesMember 2022-10-06 2022-10-07 0001211805
us-gaap:SubsequentEventMember MYSZ:SharePurchaseAgreementMember
MYSZ:NaizBespokeTechnologiesMember srt:MaximumMember 2022-10-06
2022-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
xbrli:pure iso4217:ILS
U.
S. Securities and Exchange Commission
Washington,
D. C. 20549
FORM
10-Q
☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended
September 30,
2022
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For
the transition period from _________ to _________
Commission
File No.
001-37370
MY SIZE, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
51-0394637 |
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer
I.D.
No.)
|
HaYarden 4,
POB 1026,
Airport City,
Israel,
7010000
(Address
of principal executive offices)
+972-3-600-9030
Registrant’s
telephone number, including area code:
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, $0.001 par value per share |
|
MYSZ |
|
Nasdaq Capital Market |
Indicate
by check mark whether the registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the
Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated filer |
☒ |
Smaller
reporting company |
☒ |
|
|
Emerging
growth company |
☐ |
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act) Yes ☐
No ☒
Indicate
the number of shares outstanding of each of the issuer’s classes of
common stock, as of the latest practicable date: as of November 8,
2022,
36,126,284 shares of common stock, par value $0.001 per
share were issued and outstanding.
MY
SIZE, INC.
INDEX
TO QUARTERLY REPORT ON FORM 10-Q
FOR
THE QUARTER ENDED SEPTEMBER 30, 2022
TABLE
OF CONTENTS
PART
I
FINANCIAL
INFORMATION
Item 1. Financial Statements.
My
Size Inc. and Subsidiaries
Condensed
Consolidated
Interim
Financial
Statements
As
of September 30, 2022
(unaudited)
U.S.
Dollars in Thousands
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed Consolidated Interim Financial Statements as of
September 30, 2022 (Unaudited)
Contents
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Balance Sheets (Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
The
accompanying notes are an integral part of the condensed
consolidated interim financial statements.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed Consolidated Interim Statements of Comprehensive
Loss (Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
The
accompanying notes are an integral part of the interim condensed
consolidated financial statements
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Statements of Changes in Stockholders’ Equity
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
|
|
Common stock |
|
|
Additional paid-in |
|
|
Accumulated other comprehensive |
|
|
Accumulated |
|
|
Total
stockholders’ |
|
|
|
Number |
|
|
Amount |
|
|
capital |
|
|
loss |
|
|
deficit |
|
|
equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2021 |
|
|
7,232,836 |
|
|
|
7 |
|
|
|
37,164 |
|
|
|
(424 |
) |
|
|
(34,671 |
) |
|
|
2,076 |
|
Stock-based compensation related to
options granted to employees and consultants |
|
|
- |
|
|
|
- |
|
|
|
350 |
|
|
|
- |
|
|
|
- |
|
|
|
350 |
|
Exercise of options granted to
employees (*) |
|
|
4,458 |
|
|
|
-* |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Restricted shares issued to
shareholder |
|
|
2,500,000 |
|
|
|
3 |
|
|
|
2,615 |
|
|
|
- |
|
|
|
- |
|
|
|
2,618 |
|
Issuance of shares, net of issuance cost of $768 |
|
|
4,580,491 |
|
|
|
4 |
|
|
|
5,031 |
|
|
|
- |
|
|
|
- |
|
|
|
5,035 |
|
Exercise of warrants |
|
|
751,802 |
|
|
|
1 |
|
|
|
821 |
|
|
|
- |
|
|
|
- |
|
|
|
822 |
|
Total
comprehensive loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(8 |
) |
|
|
(7,805 |
) |
|
|
(7,813 |
) |
Balance as of September 30,
2021 |
|
|
15,069,587 |
|
|
|
15 |
|
|
|
45,981 |
|
|
|
(432 |
) |
|
|
(42,476 |
) |
|
|
3,088 |
|
(*) |
Represents
an amount less than $1 |
|
|
Common
stock |
|
|
Additional
paid-in |
|
|
Accumulated
other comprehensive |
|
|
Accumulated |
|
|
Total
stockholders’ |
|
|
|
Number |
|
|
Amount |
|
|
capital |
|
|
loss |
|
|
deficit |
|
|
equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
as of July 1, 2022 |
|
|
25,551,906 |
|
|
|
26 |
|
|
|
57,048 |
|
|
|
(284 |
) |
|
|
(49,095 |
) |
|
|
7,695 |
|
Stock-based
compensation related to options granted to employees and
consultants |
|
|
- |
|
|
|
- |
|
|
|
165 |
|
|
|
- |
|
|
|
- |
|
|
|
165 |
|
Issuance
of shares in Business Combination (*)
(**) |
(**) |
|
174,378 |
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance
of shares in Business Combination |
(**) |
|
174,378 |
|
|
|
-* |
|
|
|
-* |
|
|
|
-* |
|
|
|
-* |
|
|
|
-* |
|
Total
comprehensive loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(300 |
) |
|
|
(2,026 |
) |
|
|
(2,326 |
) |
Balance
as of September 30, 2022 |
|
|
25,726,284 |
|
|
|
26 |
|
|
|
57,213 |
|
|
|
(584 |
) |
|
|
(51,121 |
) |
|
|
5,534 |
|
(*) |
See
note 6 a. |
(**) |
Represents an amount
less than $1 |
|
|
Common stock |
|
|
Additional paid-in |
|
|
Accumulated other comprehensive |
|
|
Accumulated |
|
|
Total
stockholders’ |
|
|
|
Number |
|
|
Amount |
|
|
capital |
|
|
loss |
|
|
deficit |
|
|
equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of July 1, 2021 |
|
|
15,038,327 |
|
|
|
15 |
|
|
|
45,838 |
|
|
|
(440 |
) |
|
|
(40,468 |
) |
|
|
4,945 |
|
Stock-based compensation related to
options granted to employees and consultants |
|
|
- |
|
|
|
- |
|
|
|
118 |
|
|
|
- |
|
|
|
- |
|
|
|
118 |
|
Exercise of options granted to
employees * |
|
|
4,458 |
|
|
|
-* |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Exercise of
warrants |
|
|
26,802 |
|
|
|
-* |
|
|
|
25 |
|
|
|
- |
|
|
|
- |
|
|
|
25 |
|
Total
comprehensive loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
8 |
|
|
|
(2,008 |
) |
|
|
(2,000 |
) |
Balance as of September 30,
2021 |
|
|
15,069,587 |
|
|
|
15 |
|
|
|
45,981 |
|
|
|
(432 |
) |
|
|
(42,476 |
) |
|
|
3,088 |
|
(*) |
Represents
an amount less than $1 |
The
accompanying notes are an integral part of the interim condensed
consolidated financial statements
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed Consolidated Interim Statements of Cash Flows
(Unaudited)
U.S.
dollars in thousands
(*) |
$6,310
relates to change in cash and cash equivalents and $11 to
change in restricted cash. |
The
accompanying notes are an integral part of the interim condensed
consolidated financial statements.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
1 - General
|
a. |
My
Size, Inc. is developing unique measurement technologies based on
algorithms with applications in a variety of areas, from the
apparel e-commerce market to the courier services market and to the
Do It Yourself smartphone and tablet apps market. The technology is
driven by proprietary algorithms which are able to calculate and
record measurements in a variety of novel ways.
Following
the acquisition of Orgad International Marketing Ltd. (“Orgad”) in
February 2022 (see note 6), the Company also operates an
omnichannel e-commerce platform.
The
Company has five subsidiaries, My Size Israel 2014 Ltd (“My Size
Israel”), Topspin Medical (Israel) Ltd., and Orgad all of which are
incorporated in Israel, and My Size LLC which was incorporated in
the Russian Federation and Naiz Bespoke Technologies, S.L., a
limited liability company incorporated under the laws of Spain (see
note 9). References to the Company include the subsidiaries unless
the context indicates otherwise.
|
|
|
|
|
b. |
During
the nine-month period ended September 30, 2022, the Company has
incurred significant losses and negative cash flows from operations
and has an accumulated deficit of $51,121. The
Company has financed its operations mainly through fundraising from
various investors.
The
Company’s management expects that the Company will continue to
generate losses and negative cash flows from operations for the
foreseeable future. Based on the projected cash flows and cash
balances as of September 30, 2022, management is of the opinion
that its existing cash will be sufficient to fund operations for a
period less than 12 months. As a result, there is substantial doubt
about the Company’s ability to continue as a going
concern.
Management’s
plans include the continued commercialization of the Company’s
products and securing sufficient financing through the sale of
additional equity securities, debt or capital inflows from
strategic partnerships. Additional funds may not be available when
the Company needs them, on terms that are acceptable to it, or at
all. If the Company is unsuccessful in commercializing its products
and securing sufficient financing, it may need to cease
operations.
The
financial statements include no adjustments for measurement or
presentation of assets and liabilities, which may be required
should the Company fail to operate as a going concern.
|
|
|
|
|
c. |
In
late 2019, a novel strain of COVID-19, also known as coronavirus,
was reported in Wuhan, China. While initially the outbreak was
largely concentrated in China, it spread globally. Many countries
around the world, including Israel, have from time to time
implemented significant governmental measures to control the spread
of the virus, including temporary closure of businesses, severe
restrictions on travel and the movement of people, and other
material limitations on the conduct of business. While the COVID-19
pandemic did not materially adversely affect the Company’s
consolidated financial results and operations during the three and
nine months ended September 30, 2022, the COVID-19 pandemic
affected the Company’s operations in 2020 and 2021. The pandemic
may continue to have an impact on the Company’s business,
operations, and financial results and conditions, directly and
indirectly, including, without limitation, impacts on the health of
the Company’s management and employees, its operations, marketing
and sales activities, and on the overall economy. The extent to
which COVID-19 impacts the Company’s operations will depend on
future developments, which are highly uncertain and cannot be
predicted with confidence, including the duration and severity of
the outbreak, and the actions that may be required to contain
COVID-19 or treat its impact. |
Note
2 - Significant
Accounting Policies
|
a. |
Unaudited
condensed consolidated financial statements: |
|
|
|
|
|
The
accompanying unaudited condensed consolidated interim financial
statements included herein have been prepared by the Company in
accordance with the rules and regulations of the United States
Securities and Exchange Commission (“SEC”). The unaudited condensed
consolidated financial statements are comprised of the financial
statements of the Company. In management’s opinion, the interim
financial data presented includes all adjustments necessary for a
fair presentation. All intercompany accounts and transactions have
been eliminated. Certain information required by U.S. generally
accepted accounting principles (“GAAP”) has been condensed or
omitted in accordance with rules and regulations of the SEC.
Operating results for the nine months ended September 30, 2022 are
not necessarily indicative of the results that may be expected for
any future period or for the year ending December 31,
2022. |
|
|
|
|
|
These
unaudited condensed consolidated financial statements should be
read in conjunction with the Company’s audited consolidated
financial statements and the notes thereto for the year ended
December 31, 2021.
|
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
2 - Significant Accounting Policies (cont.)
|
b. |
Significant
Accounting Policies: |
|
|
|
|
|
The
significant accounting policies followed in the preparation of
these unaudited interim condensed consolidated financial statements
are identical to those applied in the preparation of the latest
annual financial statements, except the following new policies
which were adopted following the business combination (see note
6): |
Inventories
are measured at the lower of cost or net realizable value. The cost
of inventories comprises of the costs incurred in bringing the
inventories to their present location and condition. Net realizable
value is the estimated selling price in the ordinary course of
business. At the point of the loss recognition, a new, lower-cost
basis for that inventory is established, and subsequent changes in
facts and circumstances do not result in the restoration or
increase in that newly established cost basis.
Since
the acquisition of Orgad (see note 6 - Business combination), the
Company’s revenues are comprised of two main categories: (1)
selling products to customers, and (2) licensing cloud-enabled
software subscriptions, associated software maintenance and
support.
Revenue from sale of products
Revenue
from sale of products is recognized at the time the related
performance obligation is satisfied by transferring a promised good
to a customer. Revenue is recognized net of allowances for refunds
and any taxes collected from customers, which are subsequently
remitted to governmental authorities. Refunds are estimated at
contract inception and updated at the end of each reporting period
if additional information becomes available. Revenue is recognized
when control of the product is transferred to the
customer.
The
Company maintains a returns policy that allows its customers to
return product within a specified period of time. The estimate of
the provision for returns is based upon historical experience with
actual returns.
Revenue from licensing
The
Company recognizes revenue in accordance with ASC Topic 606,
Revenues from Contracts with Customers (“ASC 606”). A contract with
a customer exists only when: the parties to the contract have
approved it and are committed to perform their respective
obligations, the Company can identify each party’s rights regarding
the distinct goods or services to be transferred (“performance
obligations”), the Company can determine the transaction price for
the goods or services to be transferred, the contract has
commercial substance and it is probable that the Company will
collect the consideration to which it will be entitled in exchange
for the goods or services that will be transferred to the
customer.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
2 - Significant Accounting Policies (cont.)
Principal versus Agent Considerations
The
Company follows the guidance provided in ASC 606 for determining
whether it is a principal or an agent in arrangements with
customers, by assessing whether the nature of the Company’s promise
is a performance obligation to provide the specified goods
(principal) or to arrange for those goods to be provided by the
other party (agent). With regard to products being sold by Orgad
through Amazon, this determination involves judgment. The Company
determined it is a principal, as it has determined that it controls
the promised product before it is transferred to the end customers,
it is primarily responsible for fulfilling the promise to provide
the goods, and it has discretion in establishing prices. Therefore,
the revenues are recorded on a gross basis.
The Company applies the provisions of ASC 805, “Business
Combination” and allocates the fair value of purchase consideration
to the tangible assets acquired, liabilities assumed, and
intangible assets acquired based on their estimated fair values.
The excess of the fair value of purchase consideration over the
fair values of these identifiable assets and liabilities is
recorded as goodwill. When determining the fair values of assets
acquired and liabilities assumed, the Company estimated the future
expected cash flows from acquired platform from a market
participant perspective, useful lives and discount rates. In
addition, management makes significant estimates and assumptions,
which are uncertain, but believed to be reasonable.
Significant estimates in valuing certain intangible assets include
but are not limited to future expected cash flows from acquired
platforms from a market participant perspective, useful lives and
discount rates. Management’s estimates of fair value are based upon
assumptions believed to be reasonable, but which are inherently
uncertain and unpredictable and, as a result, actual results may
differ from estimates.
Acquisition-related costs are recognized separately from the
acquisition and are expensed as incurred.
Goodwill
represents the excess of the purchase price over the fair value of
the net tangible and intangible assets acquired in a business
combination. Under ASC 350, “Intangible - Goodwill and Other”,
goodwill is not amortized, but rather is subject to an annual
impairment test.
ASC
350 requires goodwill to be tested for impairment at the reporting
unit level at least annually, the fourth quarter, or between annual tests
in certain circumstances, and written down when impaired. Goodwill
is tested for impairment by comparing the fair value of the
reporting unit with it carrying value.
ASC
350 allows an entity
to first assess qualitative factors to determine whether it is
necessary to perform the two-step quantitative goodwill impairment
test. If the qualitative assessment does not result in a more
likely than not indication of impairment, no further impairment
testing is required. If it does result in a more likely than not
indication of impairment, the two-step impairment test is
performed. Goodwill is not deductible for income tax purposes.
Goodwill is allocated to the fashion and equipment e-commerce
platform segment.
Alternatively, ASC
350 permits an entity to bypass the qualitative assessment for any
reporting unit and proceed directly to performing the first step of
the goodwill impairment test. There were no impairment charges to
goodwill during the period presented.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
2 - Significant Accounting Policies (cont.)
Intangible
assets consist of identifiable intangible assets that the Company
has acquired from previous business combinations. Intangible assets
are recorded at costs, net of accumulated amortization. The Company
amortizes its intangible assets reflecting the pattern in which the
economic benefits of the intangible assets are consumed. When a
pattern cannot be reliably determined, the Company uses a
straight-line amortization method.
The
estimated useful lives of the company’s intangible assets are as
follows:
Schedule of Intangible Assets Estimated Useful
Lives
Each
period the Company evaluates the estimated remaining useful lives
of its intangible assets and whether events or changes in
circumstances warrant a revision to the remaining period of
amortization
The
preparation of consolidated financial statements in conformity with
GAAP requires us to make estimates and assumptions that affect the
amounts reported and disclosed in the financial statements and the
accompanying notes. Actual results could differ materially from
these estimates.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
3 - Financial
Instruments
The
carrying amounts of cash and cash equivalents, accounts receivable,
other receivables, trade payables and accounts payable approximate
their fair value due to the short-term maturities of such
instruments.
The
Company holds share certificates in iMine Corporation (“iMine”)
formerly known as Diamante Minerals, Inc., a publicly traded
company on the OTCQB.
Due
to sales restrictions on the sale of the iMine shares, the fair
value of the shares was measured on the basis of the quoted market
price for an otherwise identical unrestricted equity instrument of
the same issuer that trades in a public market, adjusted to reflect
the effect of the sales restrictions and is therefore, ranked as
Level 2 assets.
Schedule of Significant Assets and Liabilities
Measured at Fair Value on Recurring Basis
|
|
September 30, 2022 |
|
|
|
Fair value hierarchy |
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Financial assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment in marketable securities (*) |
|
|
- |
|
|
|
80 |
|
|
|
- |
|
|
|
September 30, 2022 |
|
|
|
Fair value hierarchy |
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Financial
liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives |
|
|
- |
|
|
|
28 |
|
|
|
- |
|
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
3 - Financial Instruments (Cont.)
|
|
December 31, 2021 |
|
|
|
Fair value hierarchy |
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Financial assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment in marketable securities (*) |
|
|
- |
|
|
|
108 |
|
|
|
- |
|
(*) |
For
the nine and three-month periods ended September 30, 2022 and 2021,
the recognized gain (loss) (based on quoted market prices with a
discount due to security restrictions on iMine shares) of the
marketable securities was ($28)
and $(17),
and $46
and $24
respectively. |
|
|
December 31, 2021 |
|
|
|
Fair value hierarchy |
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Financial liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives |
|
|
- |
|
|
|
2 |
|
|
|
- |
|
Note
4 - Stock Based
Compensation
The
stock-based expense equity awards recognized in the financial
statements for services received is related to Cost of Revenues,
Research and Development, Sales and Marketing and General and
Administrative expenses as shown in the following table:
Schedule of Stock Based Compensation
Expenses
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
|
|
|
Nine
months ended
September
30,
|
|
|
Three
months ended
September
30,
|
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation
expense – Cost of revenues |
|
|
67 |
|
|
|
- |
|
|
|
39 |
|
|
|
- |
|
Stock-based compensation expense -
Research and development |
|
|
22 |
|
|
|
103 |
|
|
|
4 |
|
|
|
33 |
|
Stock-based compensation expense -
Sales and marketing |
|
|
115 |
|
|
|
164 |
|
|
|
57 |
|
|
|
71 |
|
Stock-based
compensation expense - General and administrative |
|
|
123 |
|
|
|
83 |
|
|
|
65 |
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
327 |
|
|
|
350 |
|
|
|
165 |
|
|
|
118 |
|
Options
issued to consultants:
|
|
In
July 2019, the Company entered into a three-year agreement with a
consultant (“Consultant14”) to provide services to the Company
including assisting the Company to promote, market and sell the
Company’s technology to potential customers. Pursuant to such
agreement and in partial consideration for such consulting
services, the Company agreed to issue to Consultant14 options to
purchase up to
2,667 shares of the Company’s common stock upon execution of
the agreement. The options are exercisable at $15.00
per share and shall vest in 3 equal instalments every twelve months
starting July 2019. Unexercised options shall expire
4 years from the effective date. |
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
4 - Stock Based Compensation (Cont.)
|
|
In
addition, the Company agreed to issue to Consultant14 options to
purchase up to 22,233
shares of the Company’s common stock upon execution of the
agreement. The options are exercisable at $1.08
per share and shall vest in 4 equal instalments every six months
starting September 2020. Unexercised options shall expire
5 years from the effective date. |
During
the nine and three-month period ended September 30,2022 and 2021,
an amount of $7
and
$10,
and
none and
$3
respectively,
were recorded by the Company as stock-based equity awards with
respect to Consultant 14.
Stock
Option Plan for Employees:
In
March 2017, the Company adopted the My Size, Inc. 2017 Equity
Incentive Plan (the “2017 Employee Plan”) pursuant to which the
Company’s Board of Directors may grant stock options to officers
and key employees. The total number of options which may be granted
to directors, officers, employees under this plan, is limited to
5,770,000
options. Stock options can be granted with an exercise price equal
to or less than the stock’s fair market value at the date of
grant.
On
May 25, 2020, the compensation committee of the Board of Directors
of the Company reduced the exercise price of outstanding options of
employees and directors of the Company for the purchase of an
aggregate of
140,237 shares
of common stock of the Company (with exercise prices ranging
between $18.15
and
$9.15)
to $1.04
per
share, which was the closing price for the Company’s common stock
on May 22, 2020, and extended the term of the foregoing options for
an additional one year from the original date of expiration. The
incremental compensation cost resulting from the repricing was
$53,
and the expenses during the nine-month period ended September 30,
2022 and 2021 were $2
and
$1.
On
August 10, 2020, the Company’s shareholders approved an increase in
the shares available for issuance under the 2017 Employee Plan from
200,000 to
1,450,000
shares. As a result, and pursuant to approval of the Company’s
compensation committee that was contingent on the foregoing
shareholder approval, the number of shares available for issuance
under the Company’s 2017 Consultant Incentive Plan was reduced from
466,667 to
216,667 shares.
On December 30, 2021, the Company’s shareholders approved an
increase in the shares available for issuance under the 2017 Equity
Incentive Plan from 1,450,000
shares to 5,770,000
shares.
On September 29, 2022, the Compensation Committee of the Company
approved grants of restricted share awards under the Company’s 2017
Equity Incentive Plan to Ronen Luzon (CEO), Or Kles (CFO), Billy
Pardo (COO), Ilia Turchinsky (CTO) and Ezequiel Javier Brandwain
(CCO), pursuant to which were issued 2,500,000
restricted shares, 600,000
restricted shares, 600,000
restricted shares, 400,000
restricted shares and 300,000
restricted shares, respectively. Each restricted share awarded
under section 102 Capital Gain Restricted Stock Award Agreement
(the “Agreement”). The restricted shares
shall vest in three equal installments on January 1, 2023, January
1, 2024 and January 1, 2025 for Ronen Luzon, Or Kles, Billy Pardo
and Ilia Turchinsky and on January 27, 2023, January 27, 2024 and
January 27, 2025 for Ezequiel Javier Brandwain, conditioned upon
continuous employment with the Company, and subject to accelerated
vesting upon a change in control of the Company.
On the same day, the Company granted five-year options to
purchase up to 250,000
ordinary shares to other employees of the Company at an exercise
price of $0.21 per share. The options
vest in over three years in three equal portions from the vesting
commencement date.
The
fair value of each option award is estimated on the date of grant
using the Binomial option-pricing model that used the weighted
average assumptions in the following table. The risk free rate for
the expected term of the option is based on the U.S. Treasury yield
curve in effect at the time of grant.
Schedule of Fair Value Assumptions of Stock
Options
|
|
2022
grants |
|
Dividend yield |
|
|
0 |
% |
Expected volatility |
|
|
96.52 |
% |
Risk-free interest |
|
|
4.06 |
% |
Contractual term of up to
(years) |
|
|
5 |
|
Suboptimal exercise multiple
(NIS) |
|
|
5 |
|
During
the nine and three-month period ended September 30, 2022, the
Company granted 4,650,000
restricted stock and stock options under the 2017 Employee Plan, no
options were exercised and options to purchase
51,873 shares
of common stock, expired.
The
total stock option compensation expense during the nine and
three-month period ended September 30, 2022 and 2021 which was
recorded was $53 and $234, and $9 and $312,
respectively.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
5 - Contingencies and
Commitments
|
a. |
On
August 7, 2018, the Company commenced an action against North
Empire LLC (“North Empire”) in the Supreme Court of the State of
New York, County of New York for breach of a Securities Purchase
Agreement (the “Agreement”) in which it is seeking damages in an
amount to be determined at trial, but in no event less than
$616
thousands. On August 2, 2018, North Empire filed a Summons with
Notice against the Company, also in the same Court, in which they
allege damages in an amount of $11.4 million
arising from an alleged breach of the Agreement. On September 6,
2018 North Empire filed a Notice of Discontinuance of the action it
had filed on August 2, 2018. On September 27, 2018, North Empire
filed an answer and asserted counterclaims in the action commenced
by the Company against them, alleging that the Company failed to
deliver stock certificates to North Empire causing damage to North
Empire in the amount of $10,958,589.
North Empire also filed a third-party complaint against the
Company’s CEO and now former Chairman of the Board asserting
similar claims against them in their individual capacities. On
October 17, 2018, the Company filed a reply to North Empire’s
counterclaims. On November 15, 2018, the Company’s CEO and now
former Chairman of the Board filed a motion to dismiss North
Empire’s third-party complaint. On January 6, 2020, the Court
granted the motion and dismissed the third-party complaint.
Discovery has been completed and both parties have filed motions
for summary judgment in connection with the claims and
counterclaims. On December 30, 2021, the Court denied both My Size
and North Empire’s motions for summary judgment, arguing there were
factual issues to be determined at trial. On January 26, 2022, the
Company filed a notice of appeal of the summary judgment decision.
The Company filed its appellant brief on or about October 26, 2022.
On February 3, 2022, the Company filed a motion to reargue the
Court’s decision denying the Company’s motion for summary judgment.
On or about March 31, 2022, North Empire filed its opposition
papers to the Company’s motion to reargue. On or about September
12, 2022 the Court issued its decision and order denying the
Company’s motion to reargue. North Empire is due to file its
opposing brief on or about December 7, 2022.
The
Company believes it is more likely than not that the counterclaims
will be denied.
|
|
|
|
|
b. |
On
July 5, 2021, the Company was served with a legal complaint filed
by Fidelity Venture Capital Ltd. and Dror Atzmon in the
Magistrate’s Court in Tel Aviv for a monetary award in an amount of
NIS 1,436,679
(approximately $450) and a
declaratory relief. The plaintiffs allege that the Company breached
its contractual obligations to pay them for services allegedly
rendered to the Company by the plaintiffs under a certain
consulting agreement dated July 2, 2014, in an amount of NIS
819,000
(approximately $256).
Additionally, the plaintiffs allege that the Company should
compensate them for losses allegedly incurred by them following
their investment in the Company’s shares issued under a certain
private offering. In the alternative, the plaintiffs move that the
court will declare the investment agreement void with full
restitution of plaintiffs’ original investment in an amount of NIS
1,329,650
(approximately $415). The
Company filed its statement of defense on October 25, 2021. The
first court preliminary hearing was held on March 1, 2022.
Following the first preliminary hearing and the Court’s comments
and recommendation, the plaintiffs filed a motion to strike out the
claim without prejudice. On March 8, 2022 the Court ordered
dismissal without prejudice of the claim. The Court also ruled that
to the extent the plaintiffs will not move within 7 days to revise
their motion do dismiss their claim “with prejudice”, the Company
will be entitled to request an order for costs. On April 11, 2022
the Court ordered the plaintiffs to pay the Company’s costs in the
amount of NIS 15,000, within
30 days. |
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
6 – Business
Combination
Acquisition of Orgad
On February 7, 2022, the Company acquired
100%
of the shares and voting interests in Orgad an omnichannel e-commerce platform.
The acquisition was designed to create an additional revenue stream
for the Company by becoming a direct e-commerce seller while
leveraging the synergies between MySizeID and Orgad’s e-commerce
platform.
The results of operations of Orgad have been included in the
consolidated financial statements since the acquisition date of
February 7, 2022. Orgad revenues included in the Company’s
consolidated statement of operations from February 7, 2022 through
September 30, 2022 were $1,797 and for the three-month period ended
September 30, 2022 were $685. If the acquisition had occurred
on January 1, 2021, management estimates that the consolidated pro
forma revenues for the year would have been $2,768, and the net loss would have
been $2,272.
|
(a) |
Consideration transferred |
The
following table summarizes the acquisition date fair value of each
major class of consideration:
Schedule of Fair value of the
Acquisition
|
|
USD |
|
|
|
Thousands |
|
Cash
(*) |
(*) |
|
300 |
|
Issuance
of shares of common stock (1,743,781
shares) (**) |
(**) |
|
457 |
|
Total
consideration transferred |
|
|
757 |
|
|
(*) |
The
cash payment is subject to working capital adjustments. |
|
|
|
|
(**) |
Quoted
price as of the acquisition date |
In
addition, the Company agreed to pay to the former owners of Orgad,
on the two-year and the three-year anniversary of the closing,
$350,000 in
each of these years provided that in the case of the second and
third instalments certain revenue targets are met and subject
further to certain downward post-closing adjustment. Furthermore,
1,743,781
shares of common stock will be issued in eight equal quarterly
instalments until the lapse of two years from closing. Additional
earn-out payments of 10% of the operating profit of
Orgad for the years 2022 and 2023 will also be paid. All of these
payments are subject to the former owners being actively engaged
with Orgad at the date such payment is due, and therefore were not
taken as part of the consideration for the business
combination.
During
the nine and three-month period ended September 30, 2022 an amount
of $328 and $201 was recorded in respect of the
cash instalments respectively, and $267 and $156 in respect of stocks issuance,
respectively.
|
(b) |
Identifiable assets acquired and liabilities
assumed |
Under the preliminary purchase price allocation, the Company
allocated the purchase price to tangible and identified intangible
assets acquired and liabilities assumed based on the preliminary
estimates of their fair values, which were determined using
generally accepted valuation techniques based on estimates and
assumptions made by management at the time of the acquisition. Such
estimates are subject to change during the measurement period which
is not expected to exceed one year. The purchase price allocation
was not finalized duo to examination of the net working capital of
Orgad at the acquisition date. Any adjustments to the preliminary
purchase price allocation identified during the measurement period
will be recognized in the period in which the adjustments are
determined.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
6 – Business Combination (Cont.)
The following table summarizes the preliminary fair value of assets
acquired and liabilities assumed as of the acquisition
date:
Schedule of Fair Value of Assets Acquired and
Liabilities
|
|
Thousands
USD |
|
Cash and Cash
Equivalent |
|
|
0 |
|
Trade receivables |
|
|
89 |
|
Other receivables |
|
|
239 |
|
Inventory |
|
|
864 |
|
Fixed assets |
|
|
55 |
|
Long-term deposits |
|
|
31 |
|
Selling platform (*) |
|
|
378 |
|
Goodwill |
|
|
268 |
|
Short-term credit |
|
|
(181 |
) |
Trade payables |
|
|
(660 |
) |
Other payables |
|
|
(101 |
) |
Long-term loan |
|
|
(138 |
) |
Deferred
Taxes |
|
|
(87 |
) |
Total net
assets acquired |
|
|
757 |
|
|
(*) |
The
estimated useful life of the selling platform is
three years. During the nine and three-month period ended
September 30,2022 an amount of $84
and $32
was recorded in respect of amortization expenses. |
|
(c) |
Acquisition-related costs |
The
Company incurred transaction costs of approximately $55 and none
during the nine-month and three-month period ended September 30,
2022 which were included in
general and administrative expenses in the consolidated statements
of income (loss), (the total amount recorded during the first
quarter of the year).
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements
(Unaudited)
U.S.
dollars in thousands (except share data and per share
data)
Note
7 – Operating
Segments
As a
result of the business combination in the reporting period (see
note 6), the Company has two reportable segments: (i) fashion and
equipment e-commerce platform, and (ii) SaaS based innovative
artificial intelligence driven measurement solutions. The fashion
and equipment e-commerce platform which represent Orgad’s activity
that was acquired by the Company, mainly operates on Amazon. The
SaaS based innovative artificial intelligence driven measurement
solutions, or SaaS Solutions operating segment consists of My Size
Inc and My Size Israel.
Information
related to the operations of the Company’s reportable operating
segments is set forth below:
Schedule of Reportable Operating
Segments
|
|
Fashion and
equipment e-commerce platform |
|
|
SaaS
Solutions
|
|
|
Total |
|
For the nine
months ended September 30, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
|
1,797 |
|
|
|
134 |
|
|
|
1,931 |
|
Operating (loss) income |
|
|
(215 |
) |
|
|
(5,517 |
) |
|
|
(5,732 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended September 30, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
|
685 |
|
|
|
41 |
|
|
|
726 |
|
Operating (loss) income |
|
|
(286 |
) |
|
|
(1,689 |
) |
|
|
(1,975 |
) |
|
|
Fashion
and equipment e-commerce platform |
|
|
SaaS
Solutions
|
|
For
September 30, 2022: |
|
|
|
|
|
|
|
|
Assets |
|
|
1,697 |
|
|
|
6,494 |
|
Note 8 – Significant events during the
reporting period
|
1. |
In
July 2022, Amazon deactivated Orgad’s Amazon U.S. store as a result
of complaints submitted due to an error in the listed manufacturer
of certain products on Orgad’s store. Orgad resolved the complaints
and the account was reinstated during September. During the
deactivation period, Orgad generated revenues through other sales
channels. |
|
2. |
In
August 2022, the Company established a joint venture (“JV”) in
Brazil with Santista Têxtil. The Company holds 51% and Santista
Têxtil holds 49% of the JV. The purpose of the JV is to serve the
Brazilian market according to the business plan that was set. Both
parties agree to make an initial investment in the JV of 1 million
BRL per the holding percentage. As of the reporting date, the JV is
in process of establishing its operation. |
Note
9 – Subsequent
events
On October 7, 2022, the Company entered into Share Purchase
Agreement (the “Agreement”) with the five shareholders of Naiz Fit
(the “Sellers”), pursuant to which the Sellers agreed to sell to
the Company all of the issued and outstanding shares of Naiz
Bespoke Technologies, S.L., a limited liability company
incorporated under the laws of Spain (“Naiz”). The acquisition of
Naiz was completed on October 11, 2022.
In consideration of the purchase of the shares of Naiz, the
agreement provides that the Sellers are entitled to receive (i) an
aggregate amount of 6,000,000
shares (the “Equity Consideration”) of the Company’s common stock
(the “Shares”), representing in the aggregate, immediately prior to
the issuance of such shares at the closing of the transaction, not
more than 19.9% of the issued
and outstanding Shares and (ii) up to US$2,050,000 in cash (the “Cash
Consideration”).
The Company shall make an additional cash payment (the “Shortfall
Value”) of $459,240 to the Sellers within 45
days of the Company’s receipt of Naiz’s 2025 audited financial
statements; provided that certain revenue targets are met.
The
Cash Consideration will be paid to the Sellers in five
installments, according to the following payment schedule: (i)
US$500,000 at closing, (ii) up to US$500,000 within 45 days of the
Company’s receipt of Naiz’s 2022 audited financial statements,
(iii) up to US$350,000 within 45 days of the Company’s receipt of
Naiz’s unaudited financial statements for the six months ended June
30, 2023, (iv) up to US$350,000 within 45 days of the Company’s
receipt of Naiz’s unaudited financial statements for the six months
ended December 31, 2023, and (v) up to US$350,000 within 45 days of
the Company’s receipt of Naiz’s 2024 audited financial statements;
provided that in the case of the second, third, fourth and fifth
installments certain revenue targets are met.
The payment of the second, third, fourth and fifth cash
installments are further subject to the continuing employment or
involvement of two of the shareholders which holds key position by
or with Naiz at the date such payment is due (except if a Key
Person is terminated from Naiz due to a Good Reason (as defined in
the Agreement).
The required information for purchase price allocation in
accordance with the FASB ASC Topic 805 is not fully presented
because the initial accounting of the business combination not yet
completed as of the date of the financial statements, due to the
short period since acquisition and since the acquiree accounting
records are not yet final.
Item
2. Management’s Discussion and Analysis of Financial Condition and
Results of Operations.
The
following discussion and analysis provide information that we
believe to be relevant to an assessment and understanding of our
results of operations and financial condition for the periods
described. This discussion should be read together with our
condensed consolidated interim financial statements and the notes
to the financial statements, which are included in this Quarterly
Report on Form 10-Q. This information should also be read in
conjunction with the information contained in our Annual Report on
Form 10-K for the year ended December 31, 2021, filed with the
Securities and Exchange Commission on March 31, 2022, or the Annual
Report, including the consolidated annual financial statements as
of December 31, 2021, and their accompanying notes included
therein.
This
Quarterly Report on Form 10-Q contains certain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, or the Securities Act, and Section 21E of the
Securities Exchange Act of 1934, as amended. Any statements in this
Quarterly Report on Form 10-Q about our expectations, beliefs,
plans, objectives, assumptions or future events or performance are
not historical facts and are forward-looking statements. These
statements are often, but not always, made through the use of words
or phrases such as “believe,” “will,” “expect,” “anticipate,”
“estimate,” “intend,” “plan” and “would.” For example, statements
concerning financial condition, possible or assumed future results
of operations, growth opportunities, industry ranking, plans and
objectives of management, markets for our common stock and future
management and organizational structure are all forward-looking
statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks, uncertainties
and assumptions that may cause actual results, levels of activity,
performance or achievements to differ materially from any results,
levels of activity, performance or achievements expressed or
implied by any forward-looking statement.
Any
forward-looking statements are qualified in their entirety by
reference to the risk factors discussed throughout this Quarterly
Report on Form 10-Q. Some of the risks, uncertainties and
assumptions that could cause actual results to differ materially
from estimates or projections contained in the forward-looking
statements include but are not limited to:
|
● |
our
history of losses and needs for additional capital to fund our
operations and our inability to obtain additional capital on
acceptable terms, or at all; |
|
|
|
|
● |
our
ability to continue as a going concern; |
|
|
|
|
● |
risks
related to the COVID-19 pandemic; |
|
|
|
|
● |
the
new and unproven nature of the measurement technology
markets; |
|
|
|
|
● |
our
ability to achieve customer adoption of our
products; |
|
|
|
|
● |
our
dependence on assets we purchased from a related party and the risk
that such assets may in the future be repurchased; |
|
|
|
|
● |
our
ability to enhance our brand and increase market
awareness; |
|
|
|
|
● |
our
ability to introduce new products and continually enhance our
product offerings; |
|
|
|
|
● |
the
success of our strategic relationships with third
parties; |
|
|
|
|
● |
information
technology system failures or breaches of our network
security; |
|
|
|
|
● |
competition
from competitors; |
|
|
|
|
● |
our
reliance on key members of our management team; |
|
|
|
|
● |
current
or future litigation; and |
|
|
|
|
● |
the
impact of the political and security situation in Israel on our
business. |
The
foregoing list sets forth some, but not all, of the factors that
could affect our ability to achieve results described in any
forward-looking statements. You should read this Quarterly Report
on Form 10-Q and the documents that we reference herein and have
filed as exhibits to the Quarterly Report on Form 10-Q completely
and with the understanding that our actual future results may be
materially different from what we expect. You should assume that
the information appearing in this Quarterly Report on Form 10-Q is
accurate as of the date hereof. Because the risk factors referred
to on page 12 of our Annual Report, could cause actual results or
outcomes to differ materially from those expressed in any
forward-looking statements made by us or on our behalf, you should
not place undue reliance on any forward-looking statements.
Further, any forward-looking statement speaks only as of the date
on which it is made, and we undertake no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which the statement is made or to reflect the
occurrence of unanticipated events. New factors emerge from time to
time, and it is not possible for us to predict which factors will
arise. In addition, we cannot assess the impact of each factor on
our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements.
Unless
the context otherwise requires, all references to “we,” “us,” “our”
or “the Company” in this Quarterly Report on Form 10-Q are to My
Size, Inc. a Delaware corporation, and its subsidiaries, including
MySize Israel 2014 Ltd, Topspin Medical (Israel) Ltd, Orgad
International Marketing Ltd., or Orgad, My Size LLC and Naiz
Bespoke Technologies, S.L taken as a whole.
Overview
We
are a creator of mobile device measurement solutions that has
developed innovative solutions designed to address shortcomings in
multiple verticals, including the e-commerce fashion/apparel,
shipping/parcel and do it yourself, or DIY, industries. Utilizing
our sophisticated algorithms within our proprietary technology, we
can calculate and record measurements in a variety of novel ways,
and most importantly, increase revenue for businesses across the
globe.
Our
solutions can be utilized to accurately take measurements of a
variety of items via a mobile device. By downloading the
application to a smartphone, the user is then able to run the
mobile device over the surface of an item the user wishes to
measure. The information is then automatically sent to a
cloud-based server where the dimensions are calculated through our
proprietary algorithms, and the accurate measurements (+ or - 2
centimeters) are then sent back to the user’s mobile device. We
believe that the commercial applications for this technology are
significant in many areas.
Currently,
we are mainly focusing on the e-commerce fashion/apparel industry.
In addition, our solutions address the shipping/parcel and DIY uses
markets.
While
we rollout our products to major retailers and apparel companies,
there is a lead time for new customers to ramp up before we can
recognize revenue. This lead time varies between customers,
especially when the customer is a tier 1 retailer, where the
integration process may take longer. Generally, first we integrate
our product into a customer’s online platform, which is followed by
piloting and implementation, and, assuming we are successful,
commercial roll-out, all of which takes time before we expect it to
impact our financial results in a meaningful way. While we have
begun generating initial sales revenue, we do not expect to
generate meaningful revenue during the upcoming quarters. Because
of the numerous risks and uncertainties associated with the success
of our market penetration and our dependence on the extent to which
MySizeID is adopted and utilized, we are unable to predict the
extent to which we will recognize revenue. We may be unable to
successfully develop or market any of our current or proposed
products or technologies, those products or technologies may not
generate any revenues, and any revenues generated may not be
sufficient for us to become profitable or thereafter maintain
profitability.
Orgad
Acquisition
On
February 7, 2022, My Size Israel 2014 Ltd, or My Size Israel,
entered into a Share Purchase Agreement, or the Orgad Agreement,
with Amar Guy Shalom and Elad Bretfeld, or the Orgad Sellers,
pursuant to which the Orgad Sellers agreed to sell to My Size
Israel all of the issued and outstanding equity of
Orgad.
Orgad
operates an omnichannel e-commerce platform engaged in online
retailing in the global market. It operates as a third-party seller
on Amazon.com, eBay and others. Orgad currently manages more than
1,000 stock-keeping units, or SKUs, mainly in fashion, apparel and
shoes, but is capable of managing tens of thousands of
SKUs.
The
Orgad Sellers are the sole title and beneficial owners of 100% of
the shares of Orgad. In consideration of the shares of Orgad, the
Orgad Sellers are entitled to receive (i) up to $1,000,000 in cash,
or the Orgad Cash Consideration, (ii) an aggregate of 2,790,049
shares, or the Orgad Equity Consideration, of our common stock, and
(iii) earn-out payments of 10% of the operating profit of Orgad for
the years 2022 and 2023. The transaction closed on the same
day.
The
Orgad Cash Consideration is payable to the Orgad Sellers in three
installments, according to the following payment schedule: (i)
$300,000 which we paid upon closing, (ii) $350,000 payable on the
two-year anniversary of the closing, and (iii) $350,000 payable on
the three-year anniversary of the closing, provided that in the
case of the second and third installments certain revenue targets
are met and subject further to certain downward post-closing
adjustment.
The
Equity Consideration is payable to the Orgad Sellers according to
the following payment schedule: (i) 1,395,025 shares were issued at
closing, and (ii) 1,395,024 shares will be issued in eight equal
quarterly installments until the lapse of two years from closing,
subject to certain downward post-closing adjustment.
The
payment of the second and third cash installments, the equity
installments and the earn out are further subject in each case to
the Orgad Sellers being actively engaged with Orgad at the date
such payment is due (except if the Orgad Sellers resign due to
reasons relating to material reduction of salary or adverse change
in their position with Orgad or its affiliates).
In
connection with the Orgad Agreement, each of the Orgad Sellers
entered into employment agreements with Orgad and six-month lock-up
agreements with us.
Naiz Bespoke Technologies Acquisition
On October 7, 2022, My Size, Inc., or My Size, entered into a Share
Purchase Agreement, or the Naiz Agreement, with Borja Cembrero
Saralegui, or Borja, Aritz Torre Garcia, or Aritz, Whitehole, S.L.,
or Whitehole, Twinbel, S.L., or Twinbel and EGI Acceleration, S.L.,
or EGI. Each of Borja, Aritz, Whitehole, Twinbel and EGI shall be
referred to as the Naiz Sellers herein. Pursuant to the Naiz
Agreement, the Naiz Sellers agreed to sell to My Size all of the
issued and outstanding equity of Naiz, a limited liability company
incorporated under the laws of Spain. The acquisition of Naiz was
completed on October 11, 2022.
In consideration of the purchase of the shares of Naiz, the Naiz
Agreement provided that the Naiz Sellers are entitled to receive
(i) an aggregate of 6,000,000 shares, or the Naiz Equity
Consideration, of My Size common stock, or the Shares, representing
in the aggregate, immediately prior to the issuance of such shares
at the closing of the transaction, not more than 19.9% of the
issued and outstanding Shares and (ii) up to US$2,050,000 in cash,
the Naiz Cash Consideration.
The Naiz Equity Consideration was issued to the Naiz Sellers at
closing of the transaction of which 2,365,800 shares of My Size
common stock were issued to Whitehole constituting 6.6% of our
outstanding shares following such issuance. The Naiz Agreement also
provides that, in the event that the actual value of the Naiz
Equity Consideration (based on the average closing price of the
Shares on the Nasdaq Capital Market over the 10 trading days prior
to the closing of the transaction, or the Equity Value Averaging
Period) is less than US$1,650,000, My Size shall make an additional
cash payment, or the Shortfall Value to the Naiz Sellers within 45
days of our receipt of Naiz’s 2025 audited financial statements;
provided that certain revenue targets are met. Following the Equity
Value Averaging Period, it was determined that the Shortfall Value
is US$459,240.
The Naiz Cash Consideration is payable to the Naiz Sellers in five
installments, according to the following payment schedule: (i)
US$500,000 at closing, (ii) up to US$500,000 within 45 days of My
Size’s receipt of Naiz’s 2022 audited financial statements, (iii)
up to US$350,000 within 45 days of My Size’s receipt of Naiz’s
unaudited financial statements for the six months ended June 30,
2023, (iv) up to US$350,000 within 45 days of My Size’s receipt of
Naiz’s unaudited financial statements for the six months ended
December 31, 2023, and (v) up to US$350,000 within 45 days of My
Size’s receipt of Naiz’s 2024 audited financial statements;
provided that in the case of the second, third, fourth and fifth
installments certain revenue targets are met.
The payment of the second, third, fourth and fifth cash
installments are further subject to the continuing employment or
involvement of Borja and Aritz, or the Key Persons, by or with Naiz
at the date such payment is due (except if a Key Person is
terminated from Naiz due to a Good Reason (as defined in the Naiz
Agreement).
The Naiz Agreement contains customary representations, warranties
and indemnification provisions. In addition, the Naiz Sellers will
be subject to non-competition and non-solicitation provisions
pursuant to which they agree not to engage in competitive
activities with respect to My Size’s business.
In connection with the Naiz Agreement, (i) each of the Naiz Sellers
entered into six-month lock-up agreements, or the Lock-Up
Agreement, with My Size, (ii) Whitehole, Twinbel and EGI entered
into a voting agreement, or the Voting Agreement, with My Size and
(iii) each of the Key Persons entered into employment agreements
and services agreements with Naiz.
The Lock-Up Agreement provides that each Naiz Seller will not, for
the six-month period following the closing of the transaction, (i)
offer, pledge, sell, contract to sell, sell any option, warrant or
contract to purchase, purchase any option, warrant or contract to
sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any Shares or any
securities convertible into or exercisable or exchangeable for
Shares in each case, that are currently or hereafter owned of
record or beneficially (including holding as a custodian) by such
Naiz Seller, or publicly disclose the intention to make any such
offer, sale, pledge, grant, transfer or disposition; or (ii) enter
into any swap, short sale, hedge or other agreement that transfers,
in whole or in part, any of the economic consequences of ownership
of such Naiz Seller’s Shares regardless of whether any such
transaction described in clause (i) or this clause (ii) is to be
settled by delivery of Shares or such other securities, in cash or
otherwise. The Lock-Up Agreement also contains an additional
three-month “dribble-out” provision that provides following the
expiration of the initial six-month lock-up period, without My
Size’s prior written consent (which My Size shall be permitted to
withhold at its sole discretion), each Naiz Seller shall not sell,
dispose of or otherwise transfer on any given day a number of
Shares representing more than the average daily trading volume of
the Shares for the rolling 30 day trading period prior to the date
on which such Seller executes a trade of the Shares.
The Voting Agreement provides that the voting of any Shares held by
each of Whitehole, Twinbel and EGI, or the Naiz Acquisition
Stockholders, will be exercised exclusively by a proxy designated
by My Size’s board of directors from time to time, or the Proxy,
and that each Naiz Acquisition Stockholder will irrevocably
designate and appoint the then-current Proxy as its sole and
exclusive attorney-in-fact and proxy to vote and exercise all
voting right with respect to the Shares held by each Naiz
Acquisition Stockholder. The Voting Agreement also provides that,
if the voting power held by the Proxy, taking into account the
proxies granted by the Naiz Acquisition Stockholders and the Shares
owned by the Proxy, represents 20% or more of the voting power of
My Size’s stockholders that will vote on an item, or the Voting
Power, then the Proxy shall vote such number of Shares in excess of
19.9% of the Voting Power in the same proportion as the Shares that
are voted by My Size’s other stockholders. The Voting Agreement
will terminate on the earliest to occur of (i) such time that such
Naiz Acquisition Stockholder no longer owns the Shares, (ii) the
sale of all or substantially all of the assets of My Size or the
consolidation or merger of My Size with or into any other business
entity pursuant to which stockholders of My Size prior to such
consolidation or merger hold less than 50% of the voting equity of
the surviving or resulting entity, (iii) the liquidation,
dissolution or winding up of the business operations of My Size,
and (iv) the filing or consent to filing of any bankruptcy,
insolvency or reorganization case or proceeding involving My Size
or otherwise seeking any relief under any laws relating to relief
from debts or protection of debtors.
Operations in Russia
In
addition to our Israel operations, we have operations in Russia
through our wholly owned subsidiary, My Size LLC. Specifically, we
undertake some of our sales and marketing using personnel located
in Russia. To date, the invasion of Ukraine by Russia has not had a
material impact on our business.
Results
of Operations
The
table below provides our results of operations for the periods
indicated.
|
|
Three months ended
September 30
|
|
|
Nine months ended
September 30
|
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
|
|
(dollars in thousands) |
|
|
(dollars in thousands) |
|
Revenues |
|
$ |
726 |
|
|
$ |
31 |
|
|
$ |
1,931 |
|
|
$ |
88 |
|
Cost of revenues |
|
|
(877 |
) |
|
|
- |
|
|
|
(1,607 |
) |
|
|
- |
|
Gross profit |
|
|
(151 |
) |
|
|
31 |
|
|
|
324 |
|
|
|
88 |
|
Research and development
expenses |
|
|
(350 |
) |
|
|
(462 |
) |
|
|
(1,152 |
) |
|
|
(3,842 |
) |
Sales and marketing |
|
|
(672 |
) |
|
|
(521 |
) |
|
|
(2,526 |
) |
|
|
(1,798 |
) |
General and
administrative |
|
|
(802 |
) |
|
|
(1,074 |
) |
|
|
(2,378 |
) |
|
|
(2,303 |
) |
Operating loss |
|
|
(1,975 |
) |
|
|
(2,026 |
) |
|
|
(5,732 |
) |
|
|
(7,855 |
) |
Financial income (expenses), net |
|
|
(51 |
) |
|
|
18 |
|
|
|
(198 |
) |
|
|
50 |
|
Net
loss |
|
$ |
(2,026 |
) |
|
$ |
(2,008 |
) |
|
$ |
(5,930 |
) |
|
$ |
(7,805 |
) |
Nine
and Three Months Ended September 30, 2022 Compared to Nine and
Three Months Ended September 30, 2021
Revenues
We
started to generate revenue in 2019 and we expect to incur
additional losses to increase our sales and marketing efforts and
to perform further research and development activities. Our
revenues for the nine months ended September 30, 2022 amounted to
$1,931,000 compared to $88,000 for the nine months ended September
30, 2021. Our revenues for the three months ended September 30,
2022 amounted to $726,000 compared to $31,000 for the three months
ended September 30, 2021. The increase was primarily attributable
to $1,797,000 in revenue generated from Orgad from February 7,
2022, the date of closing of the Orgad acquisition, or the
Acquisition Date, through to the end of the third quarter 2022 and
to $685,000 in revenue generated from Orgad for the three months
ended September 30, 2022.
Cost Of Revenues
Our
cost of revenues expenses for the nine and three months ended
September 30, 2022 amounted to $1,607,000 and $877,000,
respectively, compared to none for the nine and three months ended
September 30, 2021. The cost of revenues includes cash and equity
liabilities expenses in the amount of $149,000 and $89,000 for the
nine and three months ended September 30, 2022 respectively. The
increase in comparison with the corresponding period was due to the
cost of goods of the revenues generated from Orgad’s
operations.
Research and Development Expenses
Our
research and development expenses for the nine months ended
September 30, 2022 amounted to $1,152,000 compared to $3,842,000
for the nine months ended September 30, 2021. The decrease in
comparison with the corresponding period primarily resulted from
share-based payment in the amount of $2,618,000 that was recorded in the
corresponding period attributed to the share issuance to Shoshana
Zigdon under the Amendment to Purchase Agreement dated May 26,
2021, and a decrease
in shared based expenses to employees.
Our
research and development expenses for the three months ended
September 30, 2022 amounted to $350,000 compared to $462,000 for
the three months ended September 30, 2021. The decrease in
comparison with the corresponding period primarily resulted from
share-based payment to employees.
Sales and Marketing Expenses
Our
sales and marketing expenses for the nine months ended September
30, 2022 amounted to $2,526,000 compared to $1,798,000 for the nine
months ended September 30, 2021. The increase in comparison with
the corresponding period was mainly due to the hiring of new
employees and expenses associated with Orgad activities,
offset by a reduction in
share-based payment expenses to employees and
consultants.
Our
sales and marketing expenses for the three months ended September
30, 2022 amounted to $672,000 compared to $521,000 for the three
months ended September 30, 2021. The increase in comparison with
the corresponding period was mainly due to expenses associated with
Orgad activities, offset by a
reduction in share-based payment expenses to employees and
consultants.
General and Administrative Expenses
Our
general and administrative expenses for the nine months ended
September 30, 2022 amounted to $2,378,000 compared to $2,303,000
for the nine months ended September 30, 2021. The increase in
comparison with the corresponding period was mainly due to expenses
associated with Orgad activities offset by a decrease in insurance
expenses and professional services expenses.
Our
general and administrative expenses for the three months ended
September 30, 2022 amounted to $802,000 compared to $1,074,000 for
the three months ended September 30, 2021. The decrease in
comparison with the corresponding period was mainly due to a
decrease in insurance offset by an increase in expenses associated
with Orgad activities.
Operating Loss
As a
result of the foregoing, for the nine months ended September 30,
2022, our operating loss was $5,732,000 a decrease of $2,123,000
compared to our operating loss for the nine months ended September
30, 2021 of $7,855,000.
As a result of the foregoing, for the three months ended September
30, 2022, our operating loss was $1,975,000 a decrease of $51,000
compared to our operating loss for the three months ended September
30, 2021 of $2,026,000.
Financial Income (Expenses), Net
Our
financial expense, net for the nine months ended September 30, 2022
amounted to $198,000 compared to financial income of $50,000 for
the nine months ended September 30, 2021. During the nine months
ended September 30, 2022, we had financial expenses mainly from
exchange rate differences and revaluation of investment in
marketable securities whereas in the corresponding period we had
financial income primarily due revaluation of investment in
marketable securities.
Our
financial expense, net for the three months ended September 30,
2022 amounted to $51,000 compared to financial income of $18,000
for the three months ended September 30, 2021. During the three
months ended September 30, 2022, we had financial income mainly
from exchange rate differences and revaluation of investment in
marketable securities whereas in the corresponding period we had
financial expenses primarily due revaluation of investment in
marketable securities and exchange rate differences offset in
income from revaluation of derivative.
Net Loss
As a
result of the foregoing, our net loss for the nine months ended
September 30, 2022 was $5,930,000, compared to a net loss of
$7,805,000 for the nine months ended September 30, 2021. The
decrease in the net loss was mainly due to the reasons mentioned
above.
As a
result of the foregoing, our net loss for the three months ended
September 30, 2022 was $2,026,000, compared to a net loss of
$2,008,000 for the three months ended September 30, 2021. The
decrease in the net loss was mainly due to the reasons mentioned
above.
Liquidity
and Capital Resources
Since
our inception, we have funded our operations primarily through
public and private offerings of debt and equity in the State of
Israel and in the U.S.
As of
September 30, 2022, we had cash, cash equivalents, and restricted
cash of $4,622,000 compared to $10,943,000 of cash, cash
equivalents and restricted cash as of December 31, 2021. This
decrease primarily resulted from our operating activities, the
acquisition of Orgad, and resources that were deployed to grow
Orgad’s business.
Cash
used in operating activities amounted to $5,858,000 for the nine
months ended September 30, 2022, compared to $3,984,000 for the
nine months ended September 30, 2021. The increase in cash used in
operating activities was mainly due to the acquisition of Orgad and
working capital.
Net
cash used in investing activities was $327,000 for the nine months
ended September 30, 2022, compared to cash provided by investing
activities of $172,000 for the nine months ended September 30,
2021. The increase from the corresponding period was mainly due to
the acquisition of Orgad offset by changes in restricted deposits
that occurred in the nine months ended September 30,
2022.
Net
cash used in financing activities was $39,000 for the nine months
ended September 30, 2022, compared to cash provided by financing
activities of $5,857,000 for the nine months ended September 30,
2021. The cash flow from financing activities for the nine months
ended September 30, 2021 resulted from the public offerings that
occurred in January 2021 and March 2021 and from proceeds that were
received from an investor for warrants that were
exercised.
We do
not have any material commitments for capital expenditures during
the next twelve months.
We
expect that we will continue to generate losses and negative cash
flows from operations for the foreseeable future. Based on the
projected cash flows and cash balances as of September 30, 2022, we
believe our existing cash will be sufficient to fund operations for
a period less than 12 months. As a result, there is substantial
doubt about our ability to continue as a going concern. We will
need to raise additional capital, which may not be available on
reasonable terms or at all. Additional capital would be used to
accomplish the following:
|
● |
finance
our current operating expenses; |
|
|
|
|
● |
pursue
growth opportunities; |
|
|
|
|
● |
hire
and retain qualified management and key employees; |
|
|
|
|
● |
respond
to competitive pressures; |
|
|
|
|
● |
comply
with regulatory requirements; and |
|
|
|
|
● |
maintain
compliance with applicable laws. |
Current
conditions in the capital markets are such that traditional sources
of capital may not be available to us when needed or may be
available only on unfavorable terms. Our ability to raise
additional capital, if needed, will depend on conditions in the
capital markets, economic conditions, the impact of the COVID-19
pandemic, the Russian invasion of Ukraine, and a number of other
factors, many of which are outside our control, and on our
financial performance. Accordingly, we cannot assure you that we
will be able to successfully raise additional capital at all or on
terms that are acceptable to us. If we cannot raise additional
capital when needed, it may have a material adverse effect on our
business, results of operations and financial condition.
To
the extent that we raise additional capital through the sale of
equity or convertible debt securities, the issuance of such
securities could result in substantial dilution for our current
stockholders. The terms of any securities issued by us in future
capital transactions may be more favorable to new investors, and
may include preferences, superior voting rights and the issuance of
warrants or other derivative securities, which may have a further
dilutive effect on the holders of any of our securities
then-outstanding. We may issue additional shares of our common
stock or securities convertible into or exchangeable or exercisable
for our common stock in connection with hiring or retaining
personnel, option or warrant exercises, future acquisitions or
future placements of our securities for capital-raising or other
business purposes. The issuance of additional securities, whether
equity or debt, by us, or the possibility of such issuance, may
cause the market price of our common stock to decline and existing
stockholders may not agree with our financing plans or the terms of
such financings. In addition, we may incur substantial costs in
pursuing future capital financing, including investment banking
fees, legal fees, accounting fees, securities law compliance fees,
printing and distribution expenses and other costs. We may also be
required to recognize non-cash expenses in connection with certain
securities we issue, such as convertible notes and warrants, which
may adversely impact our financial condition. Furthermore, any
additional debt or equity financing that we may need may not be
available on terms favorable to us, or at all. If we are unable to
obtain such additional financing on a timely basis, we may have to
curtail our development activities and growth plans and/or be
forced to sell assets, perhaps on unfavorable terms, or we may have
to cease our operations, which would have a material adverse effect
on our business, results of operations and financial
condition.
We
have not entered into any transactions with unconsolidated entities
in which we have financial guarantees, subordinated retained
interests, derivative instruments or other contingent arrangements
that expose us to material continuing risks, contingent liabilities
or any other obligations under a variable interest in an
unconsolidated entity that provides us with financing, liquidity,
market risk or credit risk support.
Critical
Accounting Estimates
Our
management’s discussion and analysis of our financial condition and
results of operations is based on our financial statements, which
we have prepared in accordance with U.S. generally accepted
accounting principles issued by the Financial Accounting Standards
Board, or FASB. The preparation of these financial statements
requires us to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial
statements, as well as the reported expenses during the reporting
periods. Actual results may differ from these estimates under
different assumptions or conditions.
Our
significant accounting policies were revenue from contracts with
customers which are more fully described in the notes to our
financial statements appearing elsewhere in this Quarterly Report
on Form 10-Q. We believe that these accounting policies discussed
are critical to our financial results and to the understanding of
our past and future performance, as these policies relate to the
more significant areas involving management’s estimates and
assumptions. We consider an accounting estimate to be critical if:
(1) it requires us to make assumptions because information was not
available at the time or it included matters that were highly
uncertain at the time we were making our estimate; and (2) changes
in the estimate could have a material impact on our financial
condition or results of operations.
Item 3. Quantitative and Qualitative Disclosure About Market
Risk.
Not
required for a smaller reporting company.
Item 4. Controls and Procedures.
Disclosure
Controls and Procedures
We
maintain disclosure controls and procedures that are designed to
ensure that information required to be disclosed in our reports
under the Securities Exchange Act of 1934, as amended, or the
Exchange Act, and the rules and regulations thereunder, is
recorded, processed, summarized and reported within the time
periods specified in the SEC’s rules and forms and that such
information is accumulated and communicated to our management,
including our principal executive officer and principal financial
officer, as appropriate, to allow for timely decisions regarding
required disclosure. In designing and evaluating the disclosure
controls and procedures, management recognizes that any controls
and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control
objectives, and management is required to apply its judgment in
evaluating the cost-benefit relationship of possible controls and
procedures.
As
required by Rule 13a-15(b) under the Exchange Act, our management,
under the supervision and with the participation of our principal
executive officer and principal financial officer, has evaluated
the effectiveness of the design and operation of our disclosure
controls and procedures (as such term is defined in Rules 13a-15(e)
and 15d-15(e) under the Exchange Act) as of September 30, 2022.
Based upon such evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and
procedures as of September 30, 2022 were effective.
Our
Chief Executive Officer and Chief Financial Officer do not expect
that our disclosure controls and procedures or our internal
controls will prevent all error or fraud. A control system, no
matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the
control system are met. Further, the design of a control system
must reflect the fact that there are resource constraints and the
benefits of controls must be considered relative to their costs.
Due to the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, have been
detected.
Changes
in Internal Controls
During
the most recent fiscal quarter, no change has occurred in our
internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, our
internal control over financial reporting.
Part
II – Other Information
Item
1. Legal Proceedings.
From
time to time, we may become involved in various lawsuits and legal
proceedings which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an
adverse result in these or other matters may arise from time to
time that may harm our business.
North Empire LLC
On
August 7, 2018, we commenced an action against North Empire LLC
(“North Empire”) in the Supreme Court of the State of New York,
County of New York for breach of a Securities Purchase Agreement
(the “Agreement”) in which we are seeking damages in an amount to
be determined at trial, but in no event less than $616,000. On
August 2, 2018, North Empire filed a Summons with Notice against
the Company, also in the same Court, in which they allege damages
in an amount of $11.4 million arising from an alleged breach of the
Agreement. On September 6, 2018 North Empire filed a Notice of
Discontinuance of the action it had filed on August 2, 2018. On
September 27, 2018, North Empire filed an answer and asserted
counterclaims in the action commenced by us against them, alleging
that we failed to deliver stock certificates to North Empire
causing damage to North Empire in the amount of $10,958,589. North
Empire also filed a third-party complaint against our CEO and now
former Chairman of the Board asserting similar claims against them
in their individual capacities. On October 17, 2018, we filed a
reply to North Empire’s counterclaims. On November 15, 2018, our
CEO and now former Chairman of the Board filed a motion to dismiss
North Empire’s third-party complaint. On January 6, 2020, the Court
granted the motion and dismissed the third-party complaint.
Discovery has been completed and both parties have filed motions
for summary judgment in connection with the claims and
counterclaims. On December 30, 2021, the Court denied both My Size
and North Empire’s motions for summary judgment, arguing there were
factual issues to be determined at trial. On January 26, 2022, we
filed a notice of appeal of the summary judgment decision. The
Company filed its appellant brief on or about October 26, 2022. On
February 3, 2022, we filed a motion to reargue the Court’s decision
denying our motion for summary judgment. On or about March 31,
2022, North Empire filed its opposition papers to our motion to
reargue. On or about May 20, 2022, we filed our reply papers, in
further support of its motion to reargue. On or about September 12,
2022 the Court issued its decision and order denying our motion to
reargue. North Empire is due to file its opposing brief on
or about December 7, 2022.
Item
1A. Risk Factors.
Not
required for a smaller reporting company.
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not
applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934 the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
My
Size, Inc. |
|
|
|
Date:
November 14, 2022 |
By: |
/s/
Ronen Luzon |
|
|
Ronen
Luzon |
|
|
Chief
Executive Officer
(Principal
Executive Officer)
|
|
|
|
Date:
November 14, 2022 |
By: |
/s/
Or Kles |
|
|
Or
Kles |
|
|
Chief
Financial Officer
(Principal
Financial and Accounting Officer)
|
My Size (NASDAQ:MYSZ)
Historical Stock Chart
From May 2023 to May 2023
My Size (NASDAQ:MYSZ)
Historical Stock Chart
From May 2022 to May 2023